NCT03666663 (SPGblock) is a Phase 4 clinical trial of Lidocaine in Migraine, sponsored by University of California, San Francisco.

Who is sponsoring NCT03666663?

NCT03666663 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT03666663?

Interventions in NCT03666663: Lidocaine, Bupivacaine, Ropivacaine, Placebo.

Is NCT03666663 still recruiting?

NCT03666663 is currently completed. Last updated 11 October 2021.

Are results published for NCT03666663?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-10-11 · How we verify

NCT03666663: SPGblock

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sphenopalatine Ganglion Blocks RCT

Completed Phase 4 Results posted Last updated 11 October 2021

What this trial tests

Phase 4 trial testing Lidocaine in Migraine in 10 participants. Completed in 8 July 2021.

Timeline

1 February 2019

Primary endpoint
8 July 2021

8 July 2021

Quick facts

Lead sponsor	University of California, San Francisco
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	10
Start date	1 February 2019
Primary completion	8 July 2021
Estimated completion	8 July 2021
Sites	1 location across United States

Drugs / interventions tested

Lidocaine — full drug profile →
Bupivacaine (BUPIVACAINE) — full drug profile →
Ropivacaine (ROPIVACAINE) — full drug profile →
Placebo

Conditions studied

Migraine — all drugs for Migraine →

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With a Reduction in Headache Days From Baseline to Month 8 of Treatment Primary · 8 months

Reduction in headache days from baseline to month 8 of treatment as self- reported by the patients (yes/no) and as per headache diary and retrospective charts review documentation

Group	Value	95% CI
Lidocaine	3
Bupivacaine	1
Ropivacaine	1
Placebo (Saline)	0

Sponsor's own description

RCT of Sphenopalatine Ganglion (SPG) Blocks using anesthetics vs. placebo for migraine.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations.
Koo J, Lim C, Oh KT. · · 2024 · cited 57× · PMID 38414526 · DOI 10.2147/ijn.s439181

Verify or expand the search:

Other trials of Lidocaine

Trials testing the same drug.

NCT07488832 — Intravenous Lidocaine Infusion in Lumbar Fusion Surgery · NA · recruiting
NCT07445191 — Efficacy of Triamcinolone-Lidocaine Mix in Trigger Points Injection of Masseter Muscle: Double-blinded, Randomized Contr · Phase 2, PHASE3 · not yet recruiting
NCT07422558 — Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain · NA · not yet recruiting
NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
NCT07355049 — The Effect of Dexmedetomidine Versus Lidocaine on Emergence Agitation. · NA · not yet recruiting

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03666663 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 11 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03666663.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing